4-Amino-4-ethyl-heptan | 65580-68-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-Amino-4-ethyl-heptan
• 英文别名: 1-Ethyl-1-n-propyl-n-butylamine；1,1-Di-n-propyl-n-propylamine；4-Ethylheptan-4-amine
• CAS: 65580-68-9
• 化学式: C₉H₂₁N
• mdl: MFCD19204624
• 分子量: 143.272
• InChiKey: MLRWFSDTMALNLK-UHFFFAOYSA-N

物化性质

• 沸点：
  181.3±8.0 °C(Predicted)
• 密度：
  0.792±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  碘苯 、 4-Amino-4-ethyl-heptan 在 水 、 palladium diacetate 、 silver trifluoroacetate 、 乙醛酸 作用下， 以 溶剂黄146 为溶剂， 反应 15.0h， 以60%的产率得到C₁₅H₂₅N
  参考文献：
  名称：

  脂肪族伯胺的位点选择性C–H芳基化通过催化瞬态导向基团实现

  摘要：

  过渡金属催化的脂肪族胺的直接C–H键官能化在有机和药物化学研究中非常重要。已经开发了多种方法用于仲和叔脂族胺的直接sp 3 C–H官能化，但是在偏远位置伯脂族胺的位点选择性官能化仍然是一个挑战。在这里，我们报道了通过未活化的sp 3上的钯催化的C–H键官能化过程，伯烷基胺的直接，高度位点选择性的γ-芳基化碳。使用乙醛酸作为廉价的，催化的和瞬态的导向基团，无需任何保护或脱保护步骤即可制备各种各样的γ-芳基化伯烷基胺。该方法无需使用预功能化的底物或化学计量的导向基团即可直接获得有机和药物化学中重要的结构基序，并在直接从市售的2-氨基-2-基合成免疫调节药物芬戈莫德的类似物中得到了证明。丙基丙烷-1,3-二醇。

  DOI：

  10.1038/nchem.2606
• 作为产物：
  描述：

  4-乙基-4-庚醇 生成 4-Amino-4-ethyl-heptan
  参考文献：
  名称：

  Pigerol; Vernieres; Broll, European Journal of Medicinal Chemistry, 1977, vol. 12, # 4, p. 351 - 359

  摘要：

  DOI：

文献信息

• Method for producing allyl compound, and ether or ester compound produced thereby
  申请人：MITSUBISHI CHEMICAL CORPORATION

  公开号：US20040147757A1

  公开（公告）日：2004-07-29

  A method for producing an allyl compound having a compositional formula different from that of an allyl starting material compound, which comprises reacting the allyl starting material compound with an oxygen nucleophilic agent in the presence of a catalyst containing at least one transition metal compound containing a transition metal selected from the group consisting of transition metals belonging to Group 8 to Group 10 of the Periodic Table and a multidentate phosphite compound.

  一种生产具有与烯丙基起始物质化合物不同的组成式的烯丙基化合物的方法，包括在存在至少一种含有从周期表第8组到第10组的过渡金属属于的过渡金属的过渡金属化合物和多齿膦酸酯化合物的催化剂的情况下，将烯丙基起始物质化合物与氧亲核试剂反应。
• Method for producing allyl compound
  申请人：MITSUBISHI CHEMICAL CORPORATION

  公开号：US20040092777A1

  公开（公告）日：2004-05-13

  A method for producing an allyl compound having a compositional formula different from that of an allyl starting material compound, which comprises reacting the allyl starting material compound with an oxygen nucleophilic agent having a structure different from that of the allyl starting material compound in the presence of a catalyst containing at least one transition metal compound containing a transition metal selected from the group consisting of transition metals belonging to Group 8 to Group 10 of the Periodic Table and a monodentate phosphite compound having a structure of the following formula (1): P(OR 1 )(OR 2 )(OR 3 )   (1) wherein R 1 , R 2 and R 3 are respectively independently an alkyl group which may have a substituent, carbon chains of R 1 , R 2 and R 3 may have at least one carbon-carbon double bond or triple bond, and at least two optional groups of R 1 , R 2 and R 3 may bond to each other to form at least one cyclic structure.

  一种制备具有与烯丙基起始材料化合物不同组成式的烯丙基化合物的方法，包括在至少包含选择自周期表8至10族过渡金属的过渡金属化合物和具有以下式（1）结构的单齿磷酸酯化合物催化剂存在下，将烯丙基起始材料化合物与具有不同于烯丙基起始材料化合物的结构的氧亲核试剂反应，其中式（1）中，R1、R2和R3分别独立地是可以具有取代基的烷基，R1、R2和R3的碳链可以具有至少一个碳-碳双键或三键，并且R1、R2和R3的至少两个可选基团可以结合形成至少一个环状结构。
• Method for producing allyl compound, and allyl compound produced thereby
  申请人：Takai Masaki

  公开号：US20050075518A1

  公开（公告）日：2005-04-07

  A method for producing an allyl compound having a compositional formula different from that of an allyl starting material compound, which comprises reacting the allyl starting material compound with a nucleophilic agent in the presence of a catalyst containing at least one transitional metal compound containing a transition metal selected from the group consisting of transition metals belonging to Group 8 to Group 10 of the Periodic Table and at least one bidentate coordinated phosphite compound selected from the group consisting of compounds having structures of the following formulae (I) to (III): wherein A 1 to A 3 are respectively independently a diarylene group having a branched alkyl group at the ortho-position, R 1 to R 6 are respectively independently an alkyl group which may have a substituent or an aryl group which may have a substituent (including a heterocyclic compound forming an aromatic 6π electron cloud on the upper and lower sides of the ring, hereinafter the same), and Z 1 to Z 3 are respectively independently an alkylene group which may have a substituent, an arylene group which may have a substituent, an alkylene-arylene group which may have a substituent or a diarylene group which may have a substituent.

  一种制备具有不同于烯丙基起始材料化合物的组成式的烯丙基化合物的方法，包括在催化剂的存在下，将烯丙基起始材料化合物与亲核试剂反应，所述催化剂包含至少一种过渡金属化合物，所述过渡金属选自周期表8到10组的过渡金属，并且至少一种双齿配位膦酸酯化合物，所述化合物具有以下式(I)到(III)中的结构，其中A1到A3分别独立地是具有支链烷基的二芳基基团，R1到R6分别独立地是可以具有取代基的烷基基团或可以具有取代基的芳基基团（包括在环上形成芳香6π电子云的杂环化合物，在此以后相同），Z1到Z3分别独立地是可以具有取代基的烷基，可以具有取代基的芳基，可以具有取代基的烷基-芳基基团或可以具有取代基的二芳基基团。
• Tissue Factor Production Inhibitor
  申请人：Terasaka Naoki

  公开号：US20080255111A1

  公开（公告）日：2008-10-16

  A medicament which has an activity of inhibiting production of tissue factor and comprises an LXR ligand as an active ingredient; and a medicament for treatment and/or prophylaxis of vascular restenosis following angioplasty, endarterectomy, percutaneous transluminal coronary angioplasty (PTCA) or stent implantation, or treatment and/or prophylaxis of blood coagulation diseases, diseases induced by platelet aggregation including stable or unstable angina pectoris, cardiovascular and cerebrovascular diseases including thromboembolism formation diseases accompanying diabetes, rethrombosis following thrombolysis, cerebral ischemic attack, infarction, stroke, ischemia-derived dementia, peripheral artery disease, thromboembolism formation diseases during use of an aorta-coronary artery bypass, glomerulosclerosis, renal embolism, tumor or cancer metastasis, which comprises an LXR ligand as an active ingredient.

  一种药物，具有抑制组织因子产生活性，包括LXR配体作为活性成分;以及用于治疗和/或预防血管再狭窄的药物，包括血管成形术，动脉内膜切除术，经皮冠状动脉成形术（PTCA）或支架植入术后的治疗和/或预防，或治疗和/或预防血液凝固疾病，包括稳定或不稳定的心绞痛，心血管和脑血管疾病，包括伴随糖尿病的血栓栓塞形成疾病，溶栓后再栓塞，脑缺血发作，梗塞，中风，缺血性痴呆，周围动脉疾病，主动脉冠状动脉旁路使用期间的血栓栓塞形成疾病，肾小球硬化，肾脏栓塞，肿瘤或癌症转移，其中包括LXR配体作为活性成分。
• Benzene Compound Having 2 or More Substituents
  申请人：Tamaki Kazuhiko

  公开号：US20080004301A1

  公开（公告）日：2008-01-03

  A superior LXR modulator is provided. A compound represented by the general formula (I): [wherein R 1 : —COR 9 (wherein R 9 : alkyl, optionally substituted alkoxy or optionally substituted amino); R 2 : H, OH, alkoxy, optionally substituted amino, etc.; R 3 : H, optionally substituted alkyl, cycloalkyl, optionally substituted alkoxy, optionally substituted amino, halogeno, etc.; R 4 and R 5 : H, optionally substituted alkyl, halogeno, etc.; R 6 and R 7 : H, alkyl; R 8 : —X 2 R 10 [wherein R 10 : —COR 11 (wherein R 11 : OH, optionally substituted alkoxy, optionally substituted amino, etc.), —SO 2 R 12 (wherein R 12 : optionally substituted alkyl, optionally substituted amino, etc.), tetrazol-5-yl, etc.; X 2 : single bond, optionally substituted alkylene, etc.]; X 1 : —NH—, —O—, —S—, etc.; Y 1 : optionally substituted phenyl, optionally substituted 5- to 6-membered aromatic heterocyclyl; Y 2 : optionally substituted aryl, optionally substituted heterocyclyl, etc.] and the like is provided.

  提供了一种优越的LXR调节剂。化合物的一般式(I)如下：[其中R1：-COR9（其中R9：烷基，可选地取代的烷氧基或可选地取代的氨基）；R2：H，OH，烷氧基，可选地取代的氨基等；R3：H，可选地取代的烷基，环烷基，可选地取代的烷氧基，可选地取代的氨基，卤素等；R4和R5：H，可选地取代的烷基，卤素等；R6和R7：H，烷基；R8：-X2R10 [其中R10：-COR11（其中R11：OH，可选地取代的烷氧基，可选地取代的氨基等），-SO2R12（其中R12：可选地取代的烷基，可选地取代的氨基等），四唑-5-基等；X2：单键，可选地取代的烷基等]；X1：-NH-，-O-，-S-等；Y1：可选地取代的苯基，可选地取代的5-至6-成员芳香杂环基；Y2：可选地取代的芳基，可选地取代的杂环基等]。